Anupam Rasayan Acquires 48.2 Percent Stake in Bliss GVS Pharma
Specialty chemicals manufacturer Anupam Rasayan India announced that it has finalized the acquisition of a 48.2 percent controlling interest in Bliss GVS Pharma for Rs.1,750 crore, representing its entry into finished dosage formulations.
The action comes after a strong first quarter, a recent acquisition in the US, and a consistent series of new product releases.
The more challenging question is whether integration, funding, and returns will remain stable in the upcoming quarters, which is something investors will be monitoring closely.
Anupam Rasayan India Limited has surpassed the 50 percent threshold in Bliss GVS Pharma Limited and currently operates the company. The chemicals manufacturer from Surat finalized the share purchase agreement made in May and acquired 5,09,84,595 Bliss shares, representing 47.95 percent of the equity. It subsequently acquired an additional 22,50,000 shares from the market at Rs 723.28 per share, a total block valued at approximately Rs 162.74 crore in cash.
The partnership with Mates Visa Consultancy Private Limited leads to them owning 5,32,36,264 shares, which accounts for 50.07 percent. The previous open offer received minimal interest, with merely 1,669 shares submitted. Bliss's board convened on the same day, acknowledged the change in control, and appointed both parties as promoters.
Till date, Anupam Rasayan has provided its chemicals to pharmaceutical companies instead of directly to patients.
Bliss alters that. The company located in Maharashtra produces suppositories, pessaries, tablets, and capsules, markets more than 150 brands, and runs six manufacturing facilities. Its submission states that it serves clients in over 60 nations, with Sub-Saharan Africa being the largest market.
Also Read: Fujiyama’s Solar Cell Plant to Boost India’s Green Supply Chain
Anupam states that it can now link its essential starting materials and intermediates to final dosage forms, and it aims to utilize the Vevoor facility to engage in regulated CDMO operations. The investor presentation estimates Bliss's FY26 revenue to be Rs 927 crore. Anupam's total consolidated revenue for that year reached Rs 2,384 crore, meaning that including Bliss could significantly change the group's scale.
The main obstacles are securing financing for the project and guaranteeing its effective implementation. The entire transaction is estimated at around Rs 1,600 crore, consisting of approximately Rs 1,300 crore via a non-voting equity instrument and close to Rs 300 crore in a term loan. The debt is minor compared to the total, but Anupam already faces a larger interest payment. Finance expenses rose to Rs 49.19 crore in Q1 FY27, up from Rs 35.67 crore the previous year.
Also Read: Ather Energy Targets Asia and Latin America With Export Push
The acquisition of Jayhawk has increased employee costs and depreciation, resulting in a decrease in the consolidated profit margin from 10 percent to 8 percent. Managing two significant acquisitions in a short span will overwhelm leadership. The upcoming results will indicate if Bliss contributes to profit or merely impacts the balance sheet.
Anupam Rasayan India Limited derived 41 percent of its consolidated revenue from specialty chemicals in life sciences, 31 percent from performance materials, and 28 percent from the fluorinated products of Tanfac, as stated in its investor presentation. In Q1 FY27, international business accounted for 36 percent of revenue.
In Q1 FY27, Anupam Rasayan India Limited's consolidated net profit rose by 5.7 percent compared to last year, totaling Rs. 51.22 crore in comparison to Rs. 48.46 crore in the corresponding period of the previous year. In comparison to Q4 FY26, the net profit has fallen by 8.5 percent, from Rs. 56.00 crores.
Also Read: Integrum Energy Infrastructure Files Papers With SEBI
The fundamental earnings per share rose by 9.4 percent and reached Rs. 3.39 compared to Rs. 3.10 documented in the equivalent quarter of the last year, FY2026.